Quia Pharma AB (publ) (STO:QUIA)
Sweden flag Sweden · Delayed Price · Currency is SEK
0.0076
-0.0008 (-9.52%)
May 14, 2025, 11:56 AM CET
-88.50%
Market Cap 14.14M
Revenue (ttm) 460.00K
Net Income (ttm) -28.93M
Shares Out 1.68B
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,964,976
Average Volume 30,942,798
Open 0.0084
Previous Close 0.0084
Day's Range 0.0071 - 0.0084
52-Week Range 0.0030 - 0.1450
Beta 0.65
RSI 45.49
Earnings Date May 22, 2025

About Quia Pharma AB

Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform. The company was formerly known as QuiaPEG Pharma... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 3
Stock Exchange Nasdaq Stockholm
Ticker Symbol QUIA
Full Company Profile

Financial Performance

In 2024, Quia Pharma AB's revenue was 460,000, a decrease of -89.48% compared to the previous year's 4.37 million. Losses were -28.93 million, 75.1% more than in 2023.

Financial Statements

News

There is no news available yet.